Veeva Systems (NYSE:VEEV) Azioni

VEEVA SYSTEMS INC-CLASS A

Veeva Systems

Veeva Sys

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

VEEV

Giovedì cruciale sui mercati: strategie e segnali pre-market per affrontare al meglio la giornata di contrattazioni.

5 titoli da monitorare per un giovedì di trading online

Veeva Systems Inc

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting <a href="https://www.veeva.com/products/veeva-clinical-platform/">Veeva Clinical Platform</a> to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.

Veeva Teams Up with Sarah Cannon to Speed Up Cancer Trials at 200+ Research Sites

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced Astellas has chosen <a href="https://www.veeva.com/products/crm-suite/crm/">Veeva Vault CRM</a>&nbsp;globally and <a href="https://www.veeva.com/cn/veeva-china-crm-suite-en/">Veeva China CRM</a> for China.
&nbsp;
"At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients."
"Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission."
Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution.

Astellas Picks Veeva's Vault CRM to Boost Global Sales and Marketing Agility

Today, Accumulus Synergy ("Accumulus") announced a strategic partnership with Veeva Systems ("Veeva") focused on enabling connectivity to help the life sciences industry more effectively exchange regulated information with national regulatory authorities (NRAs) around the world. The partnership aims to empower customers with the tools needed to meet today's regulatory interoperability demands while maintaining the flexibility to adapt to the evolving regulatory technology landscape.
"Our partnership with Veeva is an important step forward in enabling our collective customers to maximize the benefit of the two technologies - Accumulus' single dossier in the cloud and Veeva's comprehensive Regulatory Information Management (RIM) platform," said Francisco Nogueira, CEO of Accumulus. "At Accumulus, we have seen tremendous cycle time improvements driven by our platform. Through this partnership, we're poised to significantly increase organizational efficiency for our customers by providing connectivity between Veeva RIM and the Accumulus platform."
The partnership is designed to bridge current requirements and emerging needs, supporting near-term connectivity while aligning with global efforts to modernize regulatory technology. It will enable life sciences organizations to seamlessly connect systems across borders and platforms without being locked into legacy approaches.
"Our customers are eager to find innovative solutions to drive efficiencies in NRA interactions and review cycles," said Marc Gabriel, Vice President, Regulatory at Veeva. "We look forward to working with Accumulus to build connections to advance the industry."
The Accumulus-Veeva partnership represents a shared vision for an ecosystem where collaboration drives progress and sponsors are empowered with meaningful solutions. Accumulus and Veeva are positioning the industry for sustainable innovation by bridging Veeva RIM and NRAs in the cloud.

Accumulus and Veeva Team Up to Speed Drug Approvals with Smarter Cloud Tools

Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $280 to $295.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Veeva Systems, Raises Price Target to $295

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares jumped 25.45%. Japan&#8217;s Nippon Steel is set to finalize its acquisition of the company at $55 per share, according to <a href="https://www.benzinga.com//node/45622810" target="_blank" rel="noreferrer noopener">sources familiar with the matter</a>.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) shares escalated 19.30% after Jefferies analyst Brent Thill upgraded the company from Hold to Buy and raised <a href="https://www.benzinga.com/quote/u/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $22 to $29</a>.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares rose 18.75% after multiple analysts raised their price forecasts on the stock. The company <a href="https://www.benzinga.com//node/45677373" target="_blank" rel="noreferrer noopener">recently raised its FY26 guidance</a>.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) shares upped 16.71% as President Donald Trump signed a suite of executive orders to <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">revive the U.S. nuclear industry</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares increased 14.88% after the company reported better-than-expected first-quarter earnings and analysts <a href="https://www.benzinga.com//node/45695903" target="_blank" rel="noreferrer noopener">raised the price forecast on the stock</a>.</li>
<li>Reddit, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock increased 14.27% after it was named among the <a href="https://www.benzinga.com//node/45679678" target="_blank" rel="noreferrer noopener">additions to the Russell 3000 index</a>.</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) stock grew 14.12% after private equity firms TPG and Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) recently bid to acquire the company, <a href="https://www.benzinga.com//node/45629538" target="_blank" rel="noreferrer noopener">valuing it at over $16 billion</a>.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) stock upped 13.12%, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.</li>
<li>Heico Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) shares were up 12.19% after the company reported <a href="https://www.benzinga.com//node/45630872" target="_blank" rel="noreferrer noopener">better-than-expected financial results</a>.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock gained 11.82% last week. It continued upward momentum following <a href="https://www.benzinga.com//node/45543602" target="_blank" rel="noreferrer noopener">strong Q1 earnings</a> and tariff <a href="https://www.benzinga.com//node/45655193" target="_blank" rel="noreferrer noopener">truce tailwinds</a>.</li>
</ol>
Photo via Shutterstock

Large Cap

Movers

BWXT

HOLX

INTU

RDDT

ULTA

United States Steel, Applovin And Ulta Beauty Are Among Top Large-Cap Gainers Last Week (May 26-May 30): Are The Others In Your Portfolio?

Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $265 to $329.

Citigroup Maintains Buy on Veeva Systems, Raises Price Target to $329

Investors with a lot of money to spend have taken a bullish stance on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VEEV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 35 uncommon options trades for Veeva Systems.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 25%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $438,641, and 22 are calls, for a total amount of $1,446,806.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $370.0 for Veeva Systems over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Veeva Systems stands at 360.07, with a total volume reaching 12,543.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Veeva Systems, situated within the strike price corridor from $200.0 to $370.0, throughout the last 30 days.
<h3>Veeva Systems Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748548852_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$16.0</td>
<td>$14.8</td>
<td>$16.0</td>
<td>$320.00</td>
<td>$195.2K</td>
<td align="right">3</td>
<td align="right">561</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$35.0</td>
<td>$36.0</td>
<td>$280.00</td>
<td>$162.0K</td>
<td align="right">111</td>
<td align="right">49</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$13.8</td>
<td>$12.6</td>
<td>$13.8</td>
<td>$320.00</td>
<td>$121.4K</td>
<td align="right">3</td>
<td align="right">964</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$45.0</td>
<td>$43.3</td>
<td>$45.0</td>
<td>$240.00</td>
<td>$90.0K</td>
<td align="right">814</td>
<td align="right">140</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$44.5</td>
<td>$43.1</td>
<td>$44.5</td>
<td>$240.00</td>
<td>$89.0K</td>
<td align="right">814</td>
<td align="right">120</td>
</tr>
</tbody>
</table>

<h3>About Veeva Systems</h3>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Where Is Veeva Systems Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,436,994, with VEEV's price up by 18.8%, positioned at $278.57.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Expert Opinions on Veeva Systems</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $272.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Veeva Systems, maintaining a target price of $300. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Veeva Systems, which currently sits at a price target of $325. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Veeva Systems, maintaining a target price of $210. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Veeva Systems, targeting a price of $230. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Veeva Systems, which currently sits at a price target of $295. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Veeva Systems options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Smart Money Is Betting Big In VEEV Options

Wells Fargo analyst Stan Berenshteyn maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $285 to $300.

Wells Fargo Maintains Overweight on Veeva Systems, Raises Price Target to $300

WIIM

Veeva Systems shares are trading higher after multiple analysts raised their price targets on the stock. The company recently raised its FY26 guidance.

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion <a href="https://www.benzinga.com/government/regulations/25/05/45672421/tariffs-blocked-by-court-but-goldman-sachs-says-trump-could-reimpose-them-within-days">of President Donald Trump&#8217;s tariffs.</a>
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) led the market after reporting a better-than-feared quarter. The artificial intelligence leader showed resilience in the face of export restrictions. Shares rose 4.3%, ranking as the second-best performer on the S&amp;P 500 and climbing to their highest level in more than three months.
By midday: 
<ul class="wp-block-list">
<li>The S&amp;P 500 was up 0.3% at 5,900.</li>
<li>The Nasdaq 100 gained 0.5%.</li>
<li>The Dow Jones Industrial Average traded flat.</li>
</ul>
<h3 class="wp-block-heading">Fresh Economic Data Adds To Mixed Tone</h3>
First-quarter U.S. gross domestic product shrank 0.2%, slightly improving from the initial 0.3% estimate. Still, it marked a sharp slowdown compared to the 2.4% growth in the last quarter of 2024, reflecting slower consumer spending and higher imports ahead of the tariffs impact.
More concerning was the labor market. Initial jobless claims for the week ending May 24 jumped to 240,000, exceeding expectations and reaching their highest level in nearly four months. Continuing claims also rose to levels last seen in November 2021, indicating potential softening in employment trends.
The U.S. dollar pulled back, nearly wiping out gains from the prior two sessions as traders reassessed the outlook for interest rates. Meanwhile, Treasury yields dropped, with the 30-year note falling to 4.92% and the 10-year yield easing to 4.42%.
Federal Reserve Chair Jerome Powell met with Trump at the White House, the Fed confirmed.
The meeting focused on recent economic developments, including inflation, employment and growth. Powell reiterated that the Fed&#8217;s policy path would remain dependent on incoming data but refrained from commenting on future rate decisions.
Gold climbed 1.1% to $3,320 per ounce, buoyed by lower yields and dollar weakness. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell below $107,000, giving up recent gains as risk appetite moderated in crypto markets.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,414.87</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,906.48</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,069.76</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,091.08</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.3% up to $589.37.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $420.98.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $520.87.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $205.62.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.4%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Shares of E.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) surged 26% Thursday afternoon, following the company&#8217;s announcement of its acquisition of lifestyle cosmetics brand Rhode.</li>
<li>Sentinel One Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) tumbled 11% after BofA Securities downgraded&nbsp;the stock from &#8216;Buy&#8217; to &#8216;Neutral&#8217; citing &#8220;weak trends and lackluster guidance&#8221; while lowering its price target from $24 to $21. </li>
</ul>
Stocks reacting to earnings included: 
<ul class="wp-block-list">
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) down 5.42%</li>
<li>Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) up 0.20%</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) up 18.45%</li>
<li>Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) up 3.17%</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) down 8.23%</li>
<li>Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) down 0.35%</li>
<li>Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) down 3.22%</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) down 7.90%</li>
<li>Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) up 5.65%</li>
<li>Hamilton Lane Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) down 11.21%</li>
<li>Roivant Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) up 5.50%</li>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) down 6.24%</li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) up 0.10%</li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">Nvidia Stock Has &#8216;Significant Upside&#8217; As AI &#8216;Godfather&#8217; Jensen Huang Delivers Another &#8216;Robust Quarter&#8217; </a></li>
</ul>
Image: Shutterstock

Equities

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Treasuries

Economics

Federal Reserve

ETFs

$BTC

BBWI

BURL

SPDR Dow Jones Industrial Average ETF Trust

HLNE

NDSN

NVDA

ROIV

SNPS

Select Sector SPDR-Consumer Discretionary

Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?

Stifel analyst David Grossman maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $272 to $295.

Stifel Maintains Buy on Veeva Systems, Raises Price Target to $295

UBS analyst Karl Keirstead maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $250 to $285.

UBS Maintains Neutral on Veeva Systems, Raises Price Target to $285

Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) posted better-than-expected earnings for the first quarter and raised the <a href="https://www.benzinga.com/quote/VEEV/earnings">outlook on Wednesday.</a>
The company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million.
"We crossed our 2025 revenue run rate goal this quarter and are progressing well toward our 2030 goal to double that and the positive impact we can have for our customers and the industry," said CFO Brian Van Wagener.
For the fiscal second quarter ending July 31, Veeva expects total revenue between $766 million and $769 million (Street View: $765.34 million), non-GAAP operating income between $335 million and $337 million and adjusted diluted EPS between $1.89 and $1.90 (Street view: $1.88).
For the full fiscal year ending January 31, 2026, the company projects total revenue between $3.09 billion and $3.10 billion versus the Street view of $3.09 billion (prior view: $3.040 billion to $3.055 billion), non-GAAP operating income of approximately $1.36 billion, and adjusted diluted EPS of around $7.63 versus the Street view of $7.56 (Prior view: $7.32).
Veeva shares jumped 18.1% to trade at $277.04 on Thursday.
These analysts made changes to their price targets on Veeva following earnings announcement.
<ul class="wp-block-list">
<li>Barclays analyst Saket Kalia maintained Veeva Systems with an Overweight rating and raised the price target from $285 to $300.</li>
<li>Morgan Stanley analyst Craig Hettenbach maintained the stock with an Underweight rating and raised the price target from $201 to $210.</li>
<li>Piper Sandler analyst Brent Bracelin maintained Veeva with an Overweight rating and raised the price target from $255 to $325.</li>
<li>Raymond James analyst Brian Peterson maintained the stock with an Outperform rating and raised the price target from $285 to $310.</li>
</ul>
Considering buying VEEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/VEEV/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-1024x586.png" alt="" class="wp-image-931996" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Veeva Systems Analysts Boost Their Forecasts After Better-Than-Expected Earnings

Truist Securities analyst Joe Meares maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Hold and raises the price target from $217 to $230.

Truist Securities Maintains Hold on Veeva Systems, Raises Price Target to $230

Raymond James analyst Brian Peterson maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $285 to $310.

Raymond James Maintains Outperform on Veeva Systems, Raises Price Target to $310

Piper Sandler analyst Brent Bracelin maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $255 to $325.

Piper Sandler Maintains Overweight on Veeva Systems, Raises Price Target to $325

Morgan Stanley analyst Craig Hettenbach maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Underweight and raises the price target from $201 to $210.

Morgan Stanley Maintains Underweight on Veeva Systems, Raises Price Target to $210

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $285 to $300.

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $300

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 15.42% on an annualized basis producing an average annual return of 26.2%. Currently, Veeva Systems has a market capitalization of $46.23 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $10,535.04 today based on a price of $284.13 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748529935_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) rose sharply during Thursday's session <a href="https://in.benzinga.com/trading-ideas/movers/25/05/45668750/why-veeva-systems-stock-is-gaining-today">following strong quarterly results.</a>
The company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million.
For the full fiscal year ending January 31, 2026, the company projects total revenue between $3.09 billion and $3.10 billion versus the Street view of $3.09 billion (prior view: $3.040 billion to $3.055 billion), non-GAAP operating income of approximately $1.36 billion, and adjusted diluted EPS of around $7.63 versus the Street view of $7.56 (Prior view: $7.32).
Veeva Systems shares jumped 19.9% to $281.10 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>ORIC Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) shares jumped 32% to $7.88 after the company announced preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944. Additionally, the company announced a $125 million private placement, which was priced at an 18% premium to its 10-day trailing volume-weighted average price.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) gained 28.2% to $25.01.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) jumped 27% to $114.92 after the company reported better-than-expected quarterly results and announced it will acquire Rhode.</li>
<li>C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) gained 26.7% to $29.22 after the company reported better-than-expected fourth-quarter financial results and announced a renewal and expansion of its joint venture with Baker Hughes for accelerated AI-driven transformations in the energy and industrial sectors.</li>
<li>Claritev Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTEV#NYSE">CTEV</a>) gained 23.6% to $32.96.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) rose 19.5% to $6.07.</li>
<li>BRP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) gained 12.1% to $40.28 after the company reported better-than-expected quarterly financial results. Additionally, the company announced that its president, CEO, and chair of the board will retire by the end of the fiscal year.</li>
<li>Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) rose 9.3% to $213.89 following upbeat quarterly results.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 6% to $122.78.</li>
<li>Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) rose 4.3% to $115.69 following strong quarterly results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Comments

Veeva Systems

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO